Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00437931
First received: February 19, 2007
Last updated: NA
Last verified: February 2007
History: No changes posted
  Purpose

Overt hyperthyroidism and hypothyroidism are associated with inverted hemodynamic changes.Regional blood flow disturbances (including intrathyroidal) were also reported in these thyroid disorders. The purpose of this study is to investigate the thyroid vascularity and blood flow by Color Flow Doppler Sonography in patients with subclinical thyroid dysfunction


Condition
Subclinical Hypothyroidism
Hyperthyroidism
Thyroid Dysfunction

Study Type: Observational
Study Design: Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Estimated Enrollment: 60
Study Start Date: February 2007
Estimated Study Completion Date: February 2008
Detailed Description:

Color Flow Doppler Sonography (CFDS) has become in the last years an increasing procedure to assess the thyroid blood flow. Previous studies showed specific changes of thyroid blood flow in hyperthyroidism, Hashimoto's thyroiditis and thyroid nodules when investigated by CFDS. Subclinical hyperthyroidism and hypothyroidism are common laboratory findings, defined by normal thyroid hormones concentrations along with ,respectively,decreased or increase Thyroid stimulating hormone (TSH) level. We purpose to investigate thyroid vascularity by CFDS in patients with subclinical hyperthyroidism or hypothyroidism and compared them with euthyroid patients.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with subclinical hypothyroidism or hyperthyroidism
  • patients with thyroid nodules and normal thyroid function

Exclusion Criteria:

  • patients who are taking thyroxine, antithyroid drugs, lithium or amiodarone
  • patients who had thyroid surgery or radioiodine therapy
  • patients with NYHA class 3 or 4 heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00437931

Contacts
Contact: Avraham Ishay, MD 972-4-6495556 ishay_av@clalit.org.il
Contact: Rafael Luboshitzky, MD 972-4-5495553 luboshitzky_r@clalit.org.il

Locations
Israel
Haemek Medical Center, Department of Radiology Not yet recruiting
Afula, Israel, 18101
Sub-Investigator: Leonid Chervinsky, MD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: Avraham Ishay, MD Haemek Medical Center, Endocrine Institute, Afula, Israel
Study Chair: Leonid Chervinsky Haemek Medical Center, Department of Radiology, Afula , Israel
Study Chair: Rafael Luboshitzky, MD Haemek Medical Center, Endocrine Institute, Afula, Israel
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00437931     History of Changes
Other Study ID Numbers: 006-07-EMC
Study First Received: February 19, 2007
Last Updated: February 19, 2007
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
hypothyroidism
hyperthyroidism
thyroid dysfunction
ultrasound
doppler

Additional relevant MeSH terms:
Hyperthyroidism
Hypothyroidism
Thyroid Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on October 30, 2014